Category: Multiple Sclerosis Research

Rafael Lara, who goes by Macho, shares his experience living with multiple sclerosis fatigue, including how it affects his daily routines, energy levels, and ability to spend quality time with his family while navigating life with MS. The post The reality of MS fatigue and its impact on daily life appeared first on Multiple Sclerosis…

The experimental drug fenebrutinib was shown to significantly outperform Aubagio (teriflunomide), an approved therapy, in reducing relapses and MRI markers of disease activity in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from a pair of largely identical Phase 3 clinical trials testing the oral BTK inhibitor globally in adults…

A team of scientists in China, attempting to understand the function of a genetic mutation commonly found in animals living at high altitudes, discovered a previously unknown mechanism key to myelin repair. The discovery could have important implications for diseases such as multiple sclerosis (MS), which is marked by inflammation that damages myelin — a…

I have written about how much I enjoyed helping my grandma tend to her garden as a child, in the years before I was diagnosed with relapsing-remitting multiple sclerosis. She instilled in me a great love for plants and for being outdoors. But with multiple sclerosis (MS) came increasing heat intolerance, and being outside under…

Mapi Pharma’s long-acting formulation of glatiramer acetate, GA Depot, may help stabilize disability scores over time in people with both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from an open-label Phase 2a clinical trial (NCT03362294) in PPMS and a pivotal Phase 3 clinical trial…

Spring is finally here and it’s time to enjoy the delicious fruits available this time of year. If you’re looking for a last-minute dish that’s healthy and requires zero cooking, this fruit salad is your new go-to. It’s crisp, refreshing, and … Continue reading → Source: blog.mymsaa.org

Medicaid coverage of highly effective disease-modifying therapies (DMTs) for multiple sclerosis (MS) varies across the U.S., with some states offering no access at all, a study reported. The research suggests that where a person lives could influence whether they receive high-efficacy therapies, which are known to better control disease activity and slow disability progression. Mihir…